Announced Tue, 29 Sept, 2026 · 13:52 IST
Zenith Drugs 26th AGM transcript: FY26 revenue up 28.5% to Rs 171 cr
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
ZENITHDRUG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
—1-day move
—
prior close
₹43.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
———+2.0——————————
Up moveDown movePending
AI summary
Zenith Drugs filed AGM transcript for Sep 29, 2026 meeting. FY26 revenue grew 28.5% to Rs 171.22 cr; EBITDA up 7% to Rs 17.26 cr. PAT fell to Rs 3.94 cr from Rs 7.16 cr due to higher depreciation from new tablet line. Debt-equity improved to 0.75 from 0.93. Company is entering chronic therapy segment with new products like Empagliflozin and Sitagliptin. Got new approvals in Afghanistan, Cambodia, Liberia and Myanmar. Working capital improved with collection days down to 143 from 175.
Likely market impact
Revenue growth strong but profit hit by depreciation from capacity expansion. Margin improvement expected as new tablet line scales up.